These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 1541551)

  • 21. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
    Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
    J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B.
    Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA
    J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
    Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
    Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis.
    Klouwens MJ; Trentelman JJ; Ersoz JI; Nieves Marques Porto F; Sima R; Hajdusek O; Thakur M; Pal U; Hovius JW
    Sci Rep; 2021 Feb; 11(1):4775. PubMed ID: 33637813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.
    Probert WS; LeFebvre RB
    Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi.
    Fikrig E; Telford SR; Wallich R; Chen M; Lobet Y; Matuschka FR; Kimsey RB; Kantor FS; Barthold SW; Spielman A; Flavell RA
    J Exp Med; 1995 Jan; 181(1):215-21. PubMed ID: 7807004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
    Luke CJ; Carner K; Liang X; Barbour AG
    J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired resistance to Borrelia burgdorferi infection in the rabbit. Comparison between outer surface protein A vaccine- and infection-derived immunity.
    Foley DM; Wang YP; Wu XY; Blanco DR; Lovett MA; Miller JN
    J Clin Invest; 1997 Apr; 99(8):2030-5. PubMed ID: 9109448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both.
    Luke CJ; Marshall MA; Zahradnik JM; Bybel M; Menefee BE; Barbour AG
    J Infect Dis; 2000 Mar; 181(3):1062-8. PubMed ID: 10720532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice.
    Fikrig E; Barthold SW; Marcantonio N; Deponte K; Kantor FS; Flavell RA
    Infect Immun; 1992 Feb; 60(2):657-61. PubMed ID: 1730500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection.
    Lovrich SD; Callister SM; DuChateau BK; Lim LC; Winfrey J; Day SP; Schell RF
    Infect Immun; 1995 Jun; 63(6):2113-9. PubMed ID: 7768589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC.
    Zhong W; Gern L; Stehle T; Museteanu C; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1999 Mar; 29(3):946-57. PubMed ID: 10092099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of human Lyme disease vaccine formulations in a mouse model.
    Telford SR; Kantor FS; Lobet Y; Barthold SW; Spielman A; Flavell RA; Fikrig E
    J Infect Dis; 1995 May; 171(5):1368-70. PubMed ID: 7751719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
    Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
    N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
    Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
    Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
    Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
    J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.